JP2020531443A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020531443A5 JP2020531443A5 JP2020508498A JP2020508498A JP2020531443A5 JP 2020531443 A5 JP2020531443 A5 JP 2020531443A5 JP 2020508498 A JP2020508498 A JP 2020508498A JP 2020508498 A JP2020508498 A JP 2020508498A JP 2020531443 A5 JP2020531443 A5 JP 2020531443A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- optionally substituted
- pharmaceutically acceptable
- acceptable salt
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 119
- 150000003839 salts Chemical class 0.000 claims description 76
- 229910052739 hydrogen Inorganic materials 0.000 claims description 51
- 239000001257 hydrogen Substances 0.000 claims description 51
- 150000002431 hydrogen Chemical class 0.000 claims description 45
- -1 substituted Chemical class 0.000 claims description 37
- 125000000217 alkyl group Chemical group 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 12
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 12
- 208000007502 anemia Diseases 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 208000007475 hemolytic anemia Diseases 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 150000001721 carbon Chemical group 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 6
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 6
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 6
- 208000035185 Hemolytic Congenital Anemia Diseases 0.000 claims description 4
- 206010060893 Hereditary haemolytic anaemia Diseases 0.000 claims description 4
- 208000002903 Thalassemia Diseases 0.000 claims description 4
- 201000001516 congenital hemolytic anemia Diseases 0.000 claims description 4
- 208000024987 familial hemolytic anemia Diseases 0.000 claims description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 4
- 208000007056 sickle cell anemia Diseases 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- 108700014121 Pyruvate Kinase Deficiency of Red Cells Proteins 0.000 claims description 3
- 206010014490 Elliptocytosis hereditary Diseases 0.000 claims description 2
- 208000018565 Hemochromatosis Diseases 0.000 claims description 2
- 208000001825 Hereditary elliptocytosis Diseases 0.000 claims description 2
- 208000004622 abetalipoproteinemia Diseases 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 208000005980 beta thalassemia Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 208000009601 hereditary spherocytosis Diseases 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 230000000422 nocturnal effect Effects 0.000 claims description 2
- 230000001314 paroxysmal effect Effects 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 7
- 208000030760 Anaemia of chronic disease Diseases 0.000 claims 1
- 208000022400 anemia due to chronic disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 0 C*C(C1=O)=CC=NCC1(C)[Rn](C)C(C)N Chemical compound C*C(C1=O)=CC=NCC1(C)[Rn](C)C(C)N 0.000 description 10
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 108020005115 Pyruvate Kinase Proteins 0.000 description 2
- 102000013009 Pyruvate Kinase Human genes 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- XOHUEYCVLUUEJJ-UHFFFAOYSA-I 2,3-Diphosphoglycerate Chemical compound [O-]P(=O)([O-])OC(C(=O)[O-])COP([O-])([O-])=O XOHUEYCVLUUEJJ-UHFFFAOYSA-I 0.000 description 1
- RTINBBNUUQZXQW-AATRIKPKSA-N CC(N)[Rn](C)/C(/C)=C/N=C Chemical compound CC(N)[Rn](C)/C(/C)=C/N=C RTINBBNUUQZXQW-AATRIKPKSA-N 0.000 description 1
- JCGZIBQMKYESAK-UHFFFAOYSA-N CCCN(C=CC(C)(C=N1)[Rn](C)C)C1=O Chemical compound CCCN(C=CC(C)(C=N1)[Rn](C)C)C1=O JCGZIBQMKYESAK-UHFFFAOYSA-N 0.000 description 1
- WHXNOIJKJFYUSM-UHFFFAOYSA-N C[n](c1c2C=NN(Cc(nc(cc3)N)c3F)C1=O)c1c2[s]c(Cc2n[nH]cc2)n1 Chemical compound C[n](c1c2C=NN(Cc(nc(cc3)N)c3F)C1=O)c1c2[s]c(Cc2n[nH]cc2)n1 WHXNOIJKJFYUSM-UHFFFAOYSA-N 0.000 description 1
- FXZBMEYGWLGHNX-UHFFFAOYSA-N C[n](c1c2C=NN(Cc3c[s]nc3)C1=O)c1c2[s]c(Cc2n[nH]cc2)n1 Chemical compound C[n](c1c2C=NN(Cc3c[s]nc3)C1=O)c1c2[s]c(Cc2n[nH]cc2)n1 FXZBMEYGWLGHNX-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023005925A JP7530453B2 (ja) | 2017-08-15 | 2023-01-18 | 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子 |
| JP2024121066A JP2024147805A (ja) | 2017-08-15 | 2024-07-26 | 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2017/097496 | 2017-08-15 | ||
| CN2017097496 | 2017-08-15 | ||
| US201862673533P | 2018-05-18 | 2018-05-18 | |
| US201862673526P | 2018-05-18 | 2018-05-18 | |
| US62/673,533 | 2018-05-18 | ||
| US62/673,526 | 2018-05-18 | ||
| PCT/US2018/000128 WO2019035864A1 (en) | 2017-08-15 | 2018-08-15 | PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF BLOOD DISORDERS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023005925A Division JP7530453B2 (ja) | 2017-08-15 | 2023-01-18 | 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020531443A JP2020531443A (ja) | 2020-11-05 |
| JP2020531443A5 true JP2020531443A5 (enExample) | 2021-09-30 |
| JP7275107B2 JP7275107B2 (ja) | 2023-05-17 |
Family
ID=63524352
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020508498A Active JP7275107B2 (ja) | 2017-08-15 | 2018-08-15 | 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子 |
| JP2020508455A Active JP7301040B2 (ja) | 2017-08-15 | 2018-08-15 | ピルビン酸キナーゼ調節因子およびその使用 |
| JP2022199462A Pending JP2023027276A (ja) | 2017-08-15 | 2022-12-14 | ピルビン酸キナーゼ調節因子およびその使用 |
| JP2023005925A Active JP7530453B2 (ja) | 2017-08-15 | 2023-01-18 | 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子 |
| JP2024121066A Pending JP2024147805A (ja) | 2017-08-15 | 2024-07-26 | 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020508455A Active JP7301040B2 (ja) | 2017-08-15 | 2018-08-15 | ピルビン酸キナーゼ調節因子およびその使用 |
| JP2022199462A Pending JP2023027276A (ja) | 2017-08-15 | 2022-12-14 | ピルビン酸キナーゼ調節因子およびその使用 |
| JP2023005925A Active JP7530453B2 (ja) | 2017-08-15 | 2023-01-18 | 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子 |
| JP2024121066A Pending JP2024147805A (ja) | 2017-08-15 | 2024-07-26 | 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子 |
Country Status (34)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3448859T (pt) | 2017-03-20 | 2019-10-25 | Forma Therapeutics Inc | Composições de pirrolopirrole como ativadores de piruvato quinase (pkr). |
| SG11202001262QA (en) | 2017-08-15 | 2020-03-30 | Agios Pharmaceuticals Inc | Pyruvate kinase activators for use in treating blood disorders |
| US12233063B2 (en) | 2017-10-20 | 2025-02-25 | The Regents Of The University Of Michigan | Compositions and methods for treating eye disorders |
| ES2989438T3 (es) | 2018-09-19 | 2024-11-26 | Novo Nordisk Healthcare Ag | Activación de la piruvato cinasa R |
| US12053458B2 (en) | 2018-09-19 | 2024-08-06 | Novo Nordisk Health Care Ag | Treating sickle cell disease with a pyruvate kinase R activating compound |
| SG11202108744WA (en) * | 2019-02-13 | 2021-09-29 | Agios Pharmaceuticals Inc | Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders |
| WO2020262419A1 (ja) * | 2019-06-26 | 2020-12-30 | 日産化学株式会社 | 電荷輸送性ワニス |
| CN114615977B (zh) | 2019-09-19 | 2025-01-14 | 诺沃挪第克健康护理股份公司 | 丙酮酸激酶r(pkr)活化组合物 |
| EP4185293A4 (en) * | 2020-07-21 | 2025-01-15 | The Regents of The University of Michigan | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE |
| CN112490502B (zh) * | 2020-12-04 | 2022-01-21 | 广州天赐高新材料股份有限公司 | 一种电解液及锂二次电池 |
| WO2022170200A1 (en) | 2021-02-08 | 2022-08-11 | Global Blood Therapeutics, Inc. | 1-(2-sulfonyl-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4h)-yl]-ethanone derivatives as pyruvate kinase (pkr) and pkm2 activators for the treatment of sickle cell disease |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| CA3231728A1 (en) * | 2021-09-30 | 2023-04-06 | Sitryx Therapeutics Limited | Novel compounds |
| IL312679A (en) * | 2021-11-16 | 2024-07-01 | Agios Pharmaceuticals Inc | Compounds for the treatment of anemia associated with MDS and other conditions |
| CN116159061A (zh) * | 2023-03-09 | 2023-05-26 | 上海市第十人民医院 | 丙酮酸激酶m2激活剂在制备预防或治疗心力衰竭的药物中的应用 |
| EP4671102A1 (en) | 2023-03-28 | 2025-12-31 | Honda Motor Co., Ltd. | METHOD FOR PROVIDING INFORMATION, PROGRAM FOR PROVIDING INFORMATION, STORAGE MEDIA AND INFORMATION PROCESSING APPARATUS |
| TW202509043A (zh) | 2023-05-15 | 2025-03-01 | 美商阿吉歐斯製藥公司 | ２－（（１ｈ－吡唑－３－基）甲基）－６－（（６－胺基吡啶－２－基）甲基）－４－甲基－４，６－二氫－５ｈ－噻唑基［５＇，４＇：４，５］吡咯并［２，３－ｄ］嗒𠯤－５－酮之結晶形式 |
| CN121443584A (zh) * | 2023-07-05 | 2026-01-30 | 安吉奥斯医药品有限公司 | 丙酮酸激酶活化剂的合成 |
| WO2025207563A1 (en) | 2024-03-27 | 2025-10-02 | Agios Pharmaceuticals, Inc. | Use of a pk activator in the treatment of sickle cell disease |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4405635A (en) | 1979-06-18 | 1983-09-20 | Merrell Dow Pharmaceuticals Inc. | 4-Aroylimidazol-2-ones and their use as pharmaceuticals |
| US4883914A (en) | 1987-08-17 | 1989-11-28 | American Cyanamid Company | Benzenesulfonyl carboxamide compounds useful as herbicidal agents |
| AU6388900A (en) | 1999-07-30 | 2001-02-19 | Abbott Gmbh & Co. Kg | 2-pyrazolin-5-ones |
| BR0013694A (pt) | 1999-09-04 | 2002-05-21 | Astrazeneca Ab | Composto, processo para a preparação de um composto, composição farmacêutica, e, uso de um composto |
| EP1972629A1 (en) * | 2007-03-23 | 2008-09-24 | Mutabilis SA | New imidazolo-heteroaryl derivatives with antibacterial properties |
| FR2933983B1 (fr) * | 2008-07-15 | 2010-08-27 | Servier Lab | Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| KR20110033299A (ko) * | 2008-07-23 | 2011-03-30 | 버텍스 파마슈티칼스 인코포레이티드 | 트리-사이클릭 피라졸로피리딘 키나제 억제제 |
| WO2010025202A1 (en) * | 2008-08-29 | 2010-03-04 | Amgen Inc. | PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF |
| JP5632379B2 (ja) * | 2008-10-09 | 2014-11-26 | アメリカ合衆国 | ヒトピルビン酸キナーゼ活性化剤 |
| EP2417123A2 (en) * | 2009-04-06 | 2012-02-15 | Agios Pharmaceuticals, Inc. | Therapeutic compositions and related methods of use |
| CR20170071A (es) | 2009-06-29 | 2017-03-28 | Agios Pharmaceuticals Inc | Compuestos terapeuticos y composiciones |
| CA2797694A1 (en) | 2010-04-29 | 2011-11-03 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Activators of human pyruvate kinase |
| JP5886310B2 (ja) | 2010-12-06 | 2016-03-16 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | Ｌｐ−ＰＬＡ２により媒介される疾患または状態の処置における使用のためのピリミジノン化合物 |
| TWI549947B (zh) | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
| ME03074B (me) * | 2011-05-03 | 2019-01-20 | Agios Pharmaceuticals Inc | Akтivatori piruvat kinaze za upotrebu u terapiji |
| CA2834692A1 (en) * | 2011-05-03 | 2012-11-08 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use in therapy |
| EP3372230B1 (en) | 2011-05-03 | 2020-08-12 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia |
| US9388164B2 (en) | 2011-05-03 | 2016-07-12 | Agios Pharmaceuticals, Inc | Methods of using pyruvate kinase activators |
| CN103930422A (zh) * | 2011-07-19 | 2014-07-16 | 无限药品股份有限公司 | 杂环化合物及其用途 |
| WO2013056153A1 (en) * | 2011-10-13 | 2013-04-18 | Kung Charles | Activators of pyruvate kinase m2 and methods of treating disease |
| US9921221B2 (en) | 2012-07-26 | 2018-03-20 | Joslin Diabetes Center, Inc. | Predicting and treating diabetic complications |
| WO2014074848A1 (en) | 2012-11-08 | 2014-05-15 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions and their use as pkm2 modulators |
| EP2951181A1 (en) * | 2013-01-30 | 2015-12-09 | Bayer Pharma Aktiengesellschaft | Amidoimidazopyridazines as mknk-1 kinase inhibitors |
| US9783529B2 (en) | 2013-03-13 | 2017-10-10 | Flatley Discovery Lab, Llc | Pyridazinone compounds and methods for the treatment of cystic fibrosis |
| WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| AR097543A1 (es) * | 2013-09-06 | 2016-03-23 | Lexicon Pharmaceuticals Inc | COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO |
| HRP20220195T1 (hr) | 2017-07-07 | 2022-04-15 | Inflazome Limited | Novi spojevi sulfonamid karboksamida |
| SG11202001262QA (en) | 2017-08-15 | 2020-03-30 | Agios Pharmaceuticals Inc | Pyruvate kinase activators for use in treating blood disorders |
| AR112475A1 (es) | 2017-08-15 | 2019-10-30 | Agios Pharmaceuticals Inc | Moduladores de piruvato quinasas y uso de los mismos |
| KR20200041942A (ko) | 2017-08-15 | 2020-04-22 | 애브비 인코포레이티드 | 거대환식 mcl-1 저해제 및 이의 용도 |
| PE20200758A1 (es) | 2017-08-15 | 2020-07-27 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3 |
| SG11202108744WA (en) * | 2019-02-13 | 2021-09-29 | Agios Pharmaceuticals Inc | Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders |
-
2018
- 2018-08-15 SG SG11202001262QA patent/SG11202001262QA/en unknown
- 2018-08-15 CN CN202310962497.4A patent/CN117186119A/zh active Pending
- 2018-08-15 MX MX2020001832A patent/MX2020001832A/es unknown
- 2018-08-15 RS RS20220003A patent/RS62871B1/sr unknown
- 2018-08-15 US US16/639,081 patent/US11590132B2/en active Active
- 2018-08-15 MX MX2020001833A patent/MX2020001833A/es unknown
- 2018-08-15 KR KR1020207007344A patent/KR102717594B1/ko active Active
- 2018-08-15 CN CN201880053315.9A patent/CN111032045B/zh active Active
- 2018-08-15 DK DK18779068.8T patent/DK3668513T3/da active
- 2018-08-15 PT PT187790688T patent/PT3668513T/pt unknown
- 2018-08-15 EP EP21207073.4A patent/EP4026838A1/en not_active Withdrawn
- 2018-08-15 ES ES18766063T patent/ES2966825T3/es active Active
- 2018-08-15 HR HRP20220039TT patent/HRP20220039T1/hr unknown
- 2018-08-15 TW TW107128431A patent/TWI796353B/zh active
- 2018-08-15 SM SM20230146T patent/SMT202300146T1/it unknown
- 2018-08-15 EP EP18766063.4A patent/EP3668881B1/en active Active
- 2018-08-15 IL IL272599A patent/IL272599B/en unknown
- 2018-08-15 PL PL18766400.8T patent/PL3668512T3/pl unknown
- 2018-08-15 LT LTEPPCT/US2018/000129T patent/LT3668512T/lt unknown
- 2018-08-15 EP EP18766400.8A patent/EP3668512B1/en active Active
- 2018-08-15 US US16/639,086 patent/US11464775B2/en active Active
- 2018-08-15 KR KR1020207007346A patent/KR102642408B1/ko active Active
- 2018-08-15 RS RS20230354A patent/RS64221B1/sr unknown
- 2018-08-15 SI SI201830914T patent/SI3668512T1/sl unknown
- 2018-08-15 DK DK18766400.8T patent/DK3668512T3/da active
- 2018-08-15 AU AU2018316588A patent/AU2018316588B2/en active Active
- 2018-08-15 AU AU2018316587A patent/AU2018316587B2/en active Active
- 2018-08-15 FI FIEP18766400.8T patent/FI3668512T3/fi active
- 2018-08-15 SG SG11202001353PA patent/SG11202001353PA/en unknown
- 2018-08-15 JP JP2020508498A patent/JP7275107B2/ja active Active
- 2018-08-15 TW TW107128429A patent/TWI790271B/zh active
- 2018-08-15 WO PCT/US2018/000129 patent/WO2019035865A1/en not_active Ceased
- 2018-08-15 CR CR20200123A patent/CR20200123A/es unknown
- 2018-08-15 HU HUE18779068A patent/HUE057178T2/hu unknown
- 2018-08-15 MD MDE20200663T patent/MD3668513T2/ro unknown
- 2018-08-15 SM SM20220023T patent/SMT202200023T1/it unknown
- 2018-08-15 CA CA3072455A patent/CA3072455A1/en active Pending
- 2018-08-15 BR BR112020003254-9A patent/BR112020003254A2/pt not_active Application Discontinuation
- 2018-08-15 TW TW111135803A patent/TWI823580B/zh active
- 2018-08-15 SI SI201830558T patent/SI3668513T1/sl unknown
- 2018-08-15 KR KR1020237028222A patent/KR102764124B1/ko active Active
- 2018-08-15 WO PCT/US2018/000128 patent/WO2019035864A1/en not_active Ceased
- 2018-08-15 ES ES18766400T patent/ES2944545T3/es active Active
- 2018-08-15 PT PT187664008T patent/PT3668512T/pt unknown
- 2018-08-15 EP EP18779068.8A patent/EP3668513B1/en active Active
- 2018-08-15 MY MYPI2020000757A patent/MY204421A/en unknown
- 2018-08-15 US US16/639,075 patent/US11364240B2/en active Active
- 2018-08-15 CN CN201880053325.2A patent/CN111032046B/zh active Active
- 2018-08-15 WO PCT/US2018/000127 patent/WO2019035863A1/en not_active Ceased
- 2018-08-15 LT LTEPPCT/US2018/000128T patent/LT3668513T/lt unknown
- 2018-08-15 PH PH1/2020/500343A patent/PH12020500343B1/en unknown
- 2018-08-15 UA UAA202001747A patent/UA126292C2/uk unknown
- 2018-08-15 JP JP2020508455A patent/JP7301040B2/ja active Active
- 2018-08-15 HR HRP20230452TT patent/HRP20230452T1/hr unknown
- 2018-08-15 HU HUE18766400A patent/HUE061910T2/hu unknown
- 2018-08-15 ES ES18779068T patent/ES2905100T3/es active Active
- 2018-08-15 PL PL18779068T patent/PL3668513T3/pl unknown
- 2018-08-15 PE PE2020000245A patent/PE20200724A1/es unknown
-
2020
- 2020-02-11 IL IL272597A patent/IL272597B/en unknown
- 2020-02-13 CL CL2020000375A patent/CL2020000375A1/es unknown
- 2020-03-12 CO CONC2020/0002961A patent/CO2020002961A2/es unknown
- 2020-03-12 CO CONC2020/0002959A patent/CO2020002959A2/es unknown
- 2020-03-13 EC ECSENADI202018487A patent/ECSP20018487A/es unknown
- 2020-11-19 US US16/952,257 patent/US11040036B2/en active Active
-
2022
- 2022-01-18 CY CY20221100039T patent/CY1124953T1/el unknown
- 2022-01-27 US US17/586,777 patent/US11872225B2/en active Active
- 2022-04-26 IL IL292530A patent/IL292530B2/en unknown
- 2022-05-16 US US17/744,806 patent/US11957680B2/en active Active
- 2022-12-14 JP JP2022199462A patent/JP2023027276A/ja active Pending
-
2023
- 2023-01-18 JP JP2023005925A patent/JP7530453B2/ja active Active
- 2023-01-20 US US18/099,311 patent/US12133853B2/en active Active
- 2023-05-03 AU AU2023202772A patent/AU2023202772B2/en active Active
-
2024
- 2024-07-26 JP JP2024121066A patent/JP2024147805A/ja active Pending
- 2024-08-16 AU AU2024205818A patent/AU2024205818A1/en not_active Abandoned
- 2024-09-12 US US18/882,884 patent/US20250144093A1/en active Pending